Using the same treatment approach, we recently showed that PARP inhibition by next-generation drugs, such as olaparib (LynparzaTM), or gene knockout blocks established asthma-like traits in mice chronically exposed to OVA or house dust mite (HDM) [15, 16]. The gene discussed is PARP1; the disease is asthma.